Theranos Needs Hard Data to Support its Defense Against New York Times Criticisms

Following the Wall Street Journal’s (NYT) critique of biomedical startup Theranos, the company released a document responding to the newspaper’s article. However, Wired argues that the startup needs to release hard data in order to fully respond to the NYT’s critique.
According to the article on Wired:

Last week, one of America’s most prestigious newspapers published a pair of blistering critiques of the country’s hottest biomedical startup. The Wall Street Journal alleged that the blood diagnostics company Theranos wasn’t operating at nearly the level of technological innovation its hype (and $9 billion valuation) had led the world to believe.
After a week of objections across various media platforms, Theranos today released a document offering a bullet-pointed rebuttal of the Journal‘s allegations (not to mention plenty of broadsides at the paper’s ethics and credibility). But the one thing the 6,000 word rebuttal does not do—and the one thing it really needed to—is provide data.
 
[…] Theranos does not offer any hard evidence. Despite all the dense regulatory nuance, the release is pretty much a rhetorical combo move. It has none of the data that would make it a proper scientific rebuttal.

Click here to read the full article on Wired.